|
Biocon's shares surged following USFDA approval for Jobevne, a biosimilar to Avastin, used in treating various cancers. This marks Biocon's seventh biosimilar approval in the U.S., strengthening its oncology portfolio. With bevacizumab sales reaching $2 billion in the U.S. in 2023, this approval signifies a major milestone for Biocon.
Category:
News and Media
BHEL share price: As per Trendlyne data, the average target price of the stock is Rs 213, which indicates an upside of 1% from the current market prices. The consensus recommendation from 18 analysts for the stock is a 'Hold'.
Category:
News and Media
Chicago Fed President Austan Goolsbee suggests a cautious approach to monetary policy amidst economic uncertainty fueled by trade tariffs. He acknowledges the tariffs' potential stagflationary impact, making policy responses complex. While not ruling out future rate adjustments, Goolsbee emphasizes the need to assess the economy's reaction to these tariffs.
Category:
News and Media
All news |
||||||||||||||||||
|